Advances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic stroke.

PubWeight™: 0.79‹?›

🔗 View Article (PMC 3725785)

Published in Stroke Res Treat on July 14, 2013

Authors

Philip B Gorelick1, Muhammad U Farooq

Author Affiliations

1: Hauenstein Neuroscience Center, 220 Cherry Street SE, Grand Rapids, MI 49503, USA ; Department of Translational Science and Molecular Medicine, Michigan State University College of Human Medicine, 333 Bostwick Avenue NE, Grand Rapids, MI 49503, USA.

Articles cited by this

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53

Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 14.49

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke (2010) 10.66

Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39

Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39

Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93

Platelet activation and atherothrombosis. N Engl J Med (2007) 6.18

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA (2011) 5.93

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12

Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57

Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med (2012) 4.37

Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost (2006) 2.99

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008) 2.98

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med (2007) 2.88

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA (2011) 2.79

Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76

Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? Stroke (1996) 2.65

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA (2011) 2.57

Aspirin resistance. Lancet (2006) 2.54

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA (2012) 2.22

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet (2011) 2.16

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol (2010) 1.92

Drug insight: aspirin resistance--fact or fashion? Nat Clin Pract Cardiovasc Med (2007) 1.76

Platelet function testing for aspirin resistance is reasonable to do: yes! Stroke (2010) 1.58

Clopidogrel efficacy and cigarette smoking status. JAMA (2012) 1.52

Intensifying platelet inhibition--navigating between Scylla and Charybdis. N Engl J Med (2007) 1.46

Antiplatelet activity should be measured routinely: no. Stroke (2009) 1.41

Pharmacogenomics and clopidogrel: irrational exuberance? JAMA (2011) 1.40

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke (2004) 1.01

Prevention of coronary and cerebral thrombosis. Miss Valley Med J (1956) 0.99

Cigarette smoking and clopidogrel interaction. Curr Cardiol Rep (2013) 0.91

Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke (2005) 0.87

The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against. Stroke (2010) 0.85

Aspirin resistance. Adv Hematol (2009) 0.83

Need for a point-of-care assay for monitoring antiplatelet and antithrombotic therapies. Stroke (2009) 0.78

Platelet function assays in stroke management: more study is needed. Stroke (2010) 0.78

Aspirin resistance in hypertensive patients. J Clin Hypertens (Greenwich) (2010) 0.77

Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality. Evid Based Med (2012) 0.77

Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition. JAMA (2012) 0.77

Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Rev Cardiovasc Ther (2013) 0.77

Antiplatelet activity. Stroke (2009) 0.76

Towards a global brief on aspirin. Lancet (2013) 0.76

Articles by these authors

Diffusion-weighted imaging: not all that glitters is gold. South Med J (2009) 1.65

Cardiac dysfunction after left permanent cerebral focal ischemia: the brain and heart connection. Stroke (2009) 1.51

Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol (2009) 1.21

Extent of intra-arterial calcification on head CT is predictive of the degree of intracranial atherosclerosis on digital subtraction angiography. Cerebrovasc Dis (2009) 1.06

Peripheral neuropathy: differential diagnosis and management. Am Fam Physician (2010) 1.00

Periodic lateralized epileptiform discharges: an initial electrographic pattern in reversible posterior leukoencephalopathy syndrome. Neurol Neurochir Pol (2008) 0.93

Delayed ischemia after subarachnoid hemorrhage: result of vasospasm alone or a broader vasculopathy? Vasc Med (2007) 0.89

Differential neuroprotective effects of carnosine, anserine, and N-acetyl carnosine against permanent focal ischemia. J Neurosci Res (2008) 0.89

Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke. Stroke (2012) 0.88

Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms. Epilepsy Res (2009) 0.85

Transcranial Doppler: an introduction for primary care physicians. J Am Board Fam Med (2007) 0.85

Frontotemporal lobar degeneration insights from neuropsychology and neuroimaging. Int Rev Neurobiol (2009) 0.84

Thrombolytic therapy in a patient with acute ischemic stroke caused by aortic dissection. Clin Neurol Neurosurg (2010) 0.82

Cardiovascular complications of the Guillain-Barré syndrome. Am J Cardiol (2009) 0.81

Stroke symptoms and risk factor awareness in high school children in Pakistan. Int J Stroke (2012) 0.80

Transcranial Doppler measurements in migraine and nitroglycerin headache. J Headache Pain (2007) 0.78

Clinical significance of serum zinc levels in cerebral ischemia. Stroke Res Treat (2011) 0.77

The WHO STEPwise Approach to Stroke Surveillance. J Coll Physicians Surg Pak (2008) 0.76

Treatment of a basilar artery occlusion with intra-arterial thrombolysis in a 3-year-old girl. Neurocrit Care (2008) 0.76

Hypothermia therapy, neuroprotection and meaningful brain recovery. J Pak Med Assoc (2008) 0.75

ABCD2 Score and Large-Artery Atherosclerosis. Neurohospitalist (2012) 0.75

Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology (2009) 0.75

Possible iatrogenic bilateral cerebral ischemic infarcts in a woman with vasculitis. J Headache Pain (2008) 0.75

Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial. Evid Based Med (2013) 0.75

The clinical significance of EEG cyclic alternating pattern during coma. J Clin Neurophysiol (2007) 0.75

Wallenberg's syndrome with extradural-extracranial origin of the posterior inferior cerebellar artery. Neurol Sci (2011) 0.75

Teaching neuroimages: thalamic aphasia syndrome. Neurology (2013) 0.75

Monocular blindness in a non-ketotic patient. Braz J Infect Dis (2008) 0.75

Role of intravenous levetiracetam in status migrainosus. J Headache Pain (2007) 0.75

A 27-year old female with a lytic skull lesion. Acta Neurol Belg (2008) 0.75

Mantle cell lymphoma and anti-MuSK-positive Myasthenia gravis. Onkologie (2011) 0.75

Hereditary neuropathy with liability to pressure palsies and amyotrophic lateral sclerosis. Neurol Sci (2009) 0.75

Simultaneous spinal cord and brain lesions. Meningioma. Am Fam Physician (2009) 0.75

Population-based approaches for reducing stroke risk. Expert Rev Cardiovasc Ther (2014) 0.75

Role of optical coherence tomography in multiple sclerosis and other neurological disorders--need more awareness among Pakistani medical professionals. J Pak Med Assoc (2007) 0.75

Minocycline has no effect on the fibrinolytic activity of alteplase. Ann Pharmacother (2005) 0.75

The effect of anticonvulsant drugs on the fibrinolytic activity of tissue plasminogen activator. Cerebrovasc Dis (2007) 0.75

Treatment of a hyperkinetic movement disorder during pregnancy with dronabinol. Parkinsonism Relat Disord (2008) 0.75

A novel mutation in the iduronate 2 sulfatase gene resulting in mucopolysaccharidosis type II and chorea: case report of two siblings. Mov Disord (2008) 0.75